Definium Therapeutics (DFTX) Net Income towards Common Stockholders (2019 - 2026)
Definium Therapeutics (DFTX) reported Net Income towards Common Stockholders of -$77.1 million for Q1 2026, down 154.05% year-over-year from $142.6 million in Q1 2025, and down 52.86% quarter-over-quarter from -$50.4 million in Q4 2025.
Definium Therapeutics (DFTX) Net Income towards Common Stockholders (2019 - 2026) Analysis & Trends
Definium Therapeutics (DFTX) has 7 years of Net Income towards Common Stockholders data on file, last reported at -$77.1 million in Q1 2026.
- Net Income towards Common Stockholders for Q1 2026 came in at -$77.1 million, down 154.05% year-over-year; the trailing twelve-month figure through Mar 2026 was -$237.5 million (down 123.19% YoY), and the FY2025 annual result was -$183.8 million, down 69.12% from the prior year.
- Net Income towards Common Stockholders fell to -$77.1 million in Q1 2026 per DFTX's latest filing, from -$50.4 million in the prior quarter.
- Over five years, Net Income towards Common Stockholders peaked at $56.9 million in Q4 2022 and troughed at -$77.1 million in Q1 2026.
- A 5-year average of -$28.4 million and a median of -$22.0 million in 2024 frame the typical range for Net Income towards Common Stockholders.
- The sharpest annual moves came in 2022 and 2025: Net Income towards Common Stockholders jumped 104.95% in 2022, then sank 205.14% in 2025.
- A 5-year view of Net Income towards Common Stockholders shows it stood at $56.9 million in 2022, then sank by 137.83% to -$21.5 million in 2023, then plunged by 61.51% to -$34.7 million in 2024, then slumped by 45.18% to -$50.4 million in 2025, then tumbled by 52.86% to -$77.1 million in 2026.
- Business Quant data shows DFTX's Net Income towards Common Stockholders at -$77.1 million in Q1 2026, -$50.4 million in Q4 2025, and -$67.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -13.56 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 2.50 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.63 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Definium Therapeutics | 2.46 Bn | 2.09 Bn | - | -77.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -77.10 Mn |
| Dec 31, 2025 | -50.44 Mn |
| Sep 30, 2025 | -67.27 Mn |
| Jun 30, 2025 | -42.74 Mn |
| Mar 31, 2025 | -30.35 Mn |
| Dec 31, 2024 | -34.74 Mn |
| Sep 30, 2024 | -22.04 Mn |
| Jun 30, 2024 | -19.30 Mn |
| Mar 31, 2024 | -54.40 Mn |
| Dec 31, 2023 | -21.51 Mn |
| Sep 30, 2023 | -20.18 Mn |
| Jun 30, 2023 | -27.87 Mn |
| Mar 31, 2023 | -19.58 Mn |
| Dec 31, 2022 | 56.86 Mn |
| Sep 30, 2022 | -16.49 Mn |
| Jun 30, 2022 | -16.96 Mn |
| Mar 31, 2022 | -18.51 Mn |
| Dec 31, 2021 | 27.74 Mn |
| Sep 30, 2021 | -17.20 Mn |
| Jun 30, 2021 | -45.25 Mn |